Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic Magicell-NK
- Development stage
- Unknown
- Lead developer
- Medigen Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic Magicell-NK is an allogeneic natural killer (NK) cell-based immunotherapy developed by Medigen Biotechnology Corp. for the treatment of pancreatic ductal adenocarcinoma (PDA) and cholangiocarcinoma in post-surgical patients. The therapy consists of ex vivo expanded and activated NK cells with a phenotype of CD3-CD56+ NK cells (>95% purity) derived from peripheral blood. The mechanism of action involves allogeneic NK cell-based cytotoxicity through multiple innate immune mechanisms including perforin and granzyme release to induce apoptosis, cytokine secretion (TNF-α and IFN-γ), and antibody-dependent cellular cytotoxicity (ADCC). It is currently in Phase 1/2 clinical development (trial CT-ANK-21) as an adjuvant therapy combined with chemotherapy (SLOG regimen) in patients with stage II or III PDA or cholangiocarcinoma following surgical resection.
- Brand names
- Magicell-NK
- Other names
- Allogeneic NK cellsMagicell-NK (allogeneic)
02
Targets
IFNGR1 (Interferon gamma receptor 1)IgG Fc (Immunoglobulin G Fc region)TNFR (TNF receptor family)
Beyond the preview
Go deeper on Allogeneic Magicell-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic Magicell-NK.